Search

Search Constraints

You searched for: Author/Creator Polilli, E.

Search Results

1. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance. (February 2019)

2. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy. Issue 1 (February 2018)

3. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors. (15th February 2015)

4. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. (17th December 2015)

5. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Issue 1 (16th February 2017)

6. Natural HCV resistance is common in Italy and differently associated to genotypes. Issue 1 (16th February 2017)

7. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy. Issue 1 (16th February 2017)

8. Prevalence of etravirine (ETR)‐RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA)1. (26th April 2013)

9. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. (February 2019)

10. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network. Issue 1 (16th February 2017)